- Home
- FTI vs INCY Comparison
FTI vs INCY Comparison
Compare FTI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTI
- INCY
- Stock Information
- Founded
- FTI 1884
- INCY 1991
- Country
- FTI United States
- INCY United States
- Employees
- FTI N/A
- INCY N/A
- Industry
- FTI Metal Fabrications
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- FTI Industrials
- INCY Health Care
- Exchange
- FTI Nasdaq
- INCY Nasdaq
- Market Cap
- FTI 16.4B
- INCY 17.0B
- IPO Year
- FTI N/A
- INCY 1993
- Fundamental
- Price
- FTI $39.53
- INCY $91.48
- Analyst Decision
- FTI Strong Buy
- INCY Buy
- Analyst Count
- FTI 12
- INCY 19
- Target Price
- FTI $42.20
- INCY $81.73
- AVG Volume (30 Days)
- FTI 4.6M
- INCY 1.7M
- Earning Date
- FTI 10-23-2025
- INCY 10-28-2025
- Dividend Yield
- FTI 0.51%
- INCY N/A
- EPS Growth
- FTI 59.09
- INCY 900.04
- EPS
- FTI 2.28
- INCY 4.37
- Revenue
- FTI $9,803,000,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- FTI $9.91
- INCY $16.41
- Revenue Next Year
- FTI $7.50
- INCY $10.86
- P/E Ratio
- FTI $17.31
- INCY $20.90
- Revenue Growth
- FTI 11.44
- INCY 18.87
- 52 Week Low
- FTI $22.12
- INCY $53.56
- 52 Week High
- FTI $41.35
- INCY $92.86
- Technical
- Relative Strength Index (RSI)
- FTI 58.76
- INCY 67.77
- Support Level
- FTI $35.29
- INCY $84.38
- Resistance Level
- FTI $41.35
- INCY $92.86
- Average True Range (ATR)
- FTI 1.34
- INCY 2.44
- MACD
- FTI 0.35
- INCY 0.35
- Stochastic Oscillator
- FTI 70.04
- INCY 86.26
About FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.